Evidence map›Paper›PMID 28408624›Full record

ArticleThe Journal of biological chemistry2017

Activated protein C inhibits neutrophil extracellular trap formation

Laura D Healy, Cristina Puy, José A Fernández, Annachiara Mitrugno, Ravi S Keshari, Nyiawung A Taku, Tiffany T Chu, Xiao Xu, András Gruber, Florea Lupu and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 109 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Neutrophil extracellular traps in homeostasis and disease.Signal transduction and targeted therapy · 2024
    Review
  12. Platelets at the intersection of inflammation and coagulation in the APC-mediated response to myocardial ischemia/reperfusion injury.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Laura D HealyFrom the Departments of Cell, Developmental & Cancer Biology and healyl@ohsu.edu.ORCID 0000-0002-3162-7100
Cristina PuyBiomedical Engineering, Oregon Health & Science University, Portland, Oregon 97230.
José A Fernándezthe Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California 92037, and.
Annachiara MitrugnoBiomedical Engineering, Oregon Health & Science University, Portland, Oregon 97230.
Ravi S Kesharithe Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104.
Nyiawung A TakuBiomedical Engineering, Oregon Health & Science University, Portland, Oregon 97230.
Tiffany T ChuBiomedical Engineering, Oregon Health & Science University, Portland, Oregon 97230.
Xiao Xuthe Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California 92037, and.
András GruberBiomedical Engineering, Oregon Health & Science University, Portland, Oregon 97230.
Florea Luputhe Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104.
John H Griffinthe Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California 92037, and.
Owen J T McCartyFrom the Departments of Cell, Developmental & Cancer Biology and.
Oregon Health & Science University · USScripps Research Institute · USOklahoma Medical Research Foundation · US

Funding

Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI COGGESHALL, KENNETH MARK · 2004 to 2023
$56.2M
Structure and Function of Protein CR01HL052246 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI GRIFFIN, JOHN H · 2005 to 2017
$9.6M
Characterization of Coagulation Factor-platelet Interactions: Role of FXIR01HL101972 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Owen J McCarty · 2010 to 2026
$8.5M
INTERACTIONS AT THE MICROBE/HOST INTERFACET32AI007472 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI LANDFEAR, SCOTT M · 1995 to 2019
$6.7M
Pilot ProjectP30GM114731 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI MCEVER, RODGER PAUL · 2016 to 2020
$6.5M
Therapeutic Protein C Activator for Myocardial IschemiaR44HL117589 · NHLBI · ARONORA, INC. · PI TUCKER, ERIK IAN, VERBOUT, NORAH · 2013 to 2019
$5.2M
FXI and SepsisR01GM116184 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI LUPU, FLOREA, MCCARTY, OWEN J · 2015 to 2018
$1.9M
NHLBI NIH HHS R01 HL052246NHLBI NIH HHS R01 HL101972NHLBI NIH HHS R44 HL117589NIAID NIH HHS T32 AI007472NIAID NIH HHS U19 AI062629NIGMS NIH HHS P30 GM114731NIGMS NIH HHS R01 GM116184
6 · The paper itself

Abstract

Activated protein C (APC) is a multifunctional serine protease with anticoagulant, cytoprotective, and anti-inflammatory activities. In addition to the cytoprotective effects of APC on endothelial cells, podocytes, and neurons, APC cleaves and detoxifies extracellular histones, a major component of neutrophil extracellular traps (NETs). NETs promote pathogen clearance but also can lead to thrombosis; the pathways that negatively regulate NETosis are largely unknown. Thus, we studied whether APC is capable of directly inhibiting NETosis via receptor-mediated cell signaling mechanisms. Here, by quantifying extracellular DNA or myeloperoxidase, we demonstrate that APC binds human leukocytes and prevents activated platelet supernatant or phorbol 12-myristate 13-acetate (PMA) from inducing NETosis. Of note, APC proteolytic activity was required for inhibiting NETosis. Moreover, antibodies against the neutrophil receptors endothelial protein C receptor (EPCR), protease-activated receptor 3 (PAR3), and macrophage-1 antigen (Mac-1) blocked APC inhibition of NETosis. Select mutations in the Gla and protease domains of recombinant APC caused a loss of NETosis. Interestingly, pretreatment of neutrophils with APC prior to induction of NETosis inhibited platelet adhesion to NETs. Lastly, in a nonhuman primate model of

Indexed as

AnimalsAntigens, CDDisease Models, AnimalEndothelial Protein C ReceptorEscherichia coliEscherichia coli InfectionsExtracellular TrapsFemaleHumansMacrophage-1 AntigenMaleNeutrophil ActivationNeutrophilsPapio anubisProtein CReceptors, Cell SurfaceAntigens, CDEndothelial Protein C ReceptorMacrophage-1 AntigenPROCR protein, humanProtein CReceptors, Cell SurfaceTetradecanoylphorbol Acetateactivated protein Ccell biologycell signalingcoagulation factorendothelial protein C receptorhemostasisMac-1neutrophilneutrophil extracellular trapsPAR3protein Cthrombosis

Identifiers

PMID28408624
PMCPMC5448091
OpenAlexW2607222622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.